Atossa遺傳學 ATOS 深 滬
等待開盤 07-18 09:30:00 美东时间
0.8695
-0.022
-2.48%
華盛通- 最 高0.93
- 今 開0.906
- 成交量 94.89万股
- 最 低 0.8695
- 昨 收 0.8916
- 總市值 1.12亿
- 52周最高 1.66
- 市盈率 靜 --
- 換手率 0.74%
- 52周最低 0.5526
- 委 比 39.58%
- 總股本 1.29亿
- 歷史最高 2232.00
- 量 比 1.32
- 振 幅 6.79%
- 歷史最低 0.50
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多姬广绪｜技术系统的在地性重构：从东京通勤梦魇到中国县域骑手的生存智慧
《通勤梦魇：东京地铁与机器的人类学》，迈克尔·菲什著，孟超、桑元峰译，上海人民出版社2025年1月出版，384页，69.00元 迈克尔·菲什在《通勤梦魇：东京地...
06-25 11:46
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
Craig-Hallum Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $4
Craig-Hallum analyst Albert Lowe initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $4.
06-06 01:15
Occidental, ADNOC's XRG Eye $500 Million Texas Carbon Capture Venture
Occidental teams up with ADNOC's XRG on a potential $500M carbon capture project in Texas during Trump's UAE visit.
05-16 23:58
Atossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer
Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profileSEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics,
05-14 20:19
Atossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year.
05-13 20:06
Atossa Therapeutics announces issuance of U.S. patent
Atossa Therapeutics (NASDAQ:ATOS) has announced that the U. S. Patent and Trademark Office has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-en...
04-22 20:52
美股大行评级 | 潜在涨幅3020.12%！Ascendiant Capital上调Plus Therapeutics目标价至20美元，维持"买入"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
04-22 08:41
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.25
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $7.25.
04-21 18:08
